Management and Prevention of Common HIV-Related Manifestations

David H. Spach, MD
Professor of Medicine
University of Washington
Seattle, WA

Financial Relationships With Commercial Entities

Dr. Spach has no financial relationships with any commercial entities. (Updated 8/5/20)

Learning Objectives

After attending this presentation, learners will be able to:

- List the preferred treatment for CAP in persons with HIV
- Discuss initiation of ART in persons with active tuberculosis
- Describe the approach to isolated hepatitis B core antibody
- Summarize pneumococcal & zoster vaccine recommendations
Community-Acquired Pneumonia in Persons with HIV

Treatment of CAP in Persons with HIV

• A 38-year-old woman with HIV is seen in clinic in the month of August with a 2-day history of cough, fever, and mild dyspnea on exertion. A COVID-19 test (NP swab) was performed the prior day and is negative.
• She is taking bictegravir-TAF-FTC. Recent HIV RNA level <40 copies/mL and CD4 count 430 cells/mm³. She has no other medical problems.
• Chest radiograph shows a focal right lower lobe infiltrate and she is diagnosed with community acquired pneumonia (CAP). She is not acutely ill.

ARS Question 1

• Based on OI Guidelines, what oral antibiotic treatment should be given for out-patient management of this woman with CAP?

1. Trimethoprim-sulfamethoxazole
2. Amoxicillin-clavulanate plus Azithromycin
3. Amoxicillin-clavulanate
4. Azithromycin
Empiric Out-Patient Treatment of CAP in Persons with HIV

<table>
<thead>
<tr>
<th>Preferred</th>
<th>Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>*Beta-lactam plus Macrolide (Azithromycin or Clarithromycin)</td>
<td>AI</td>
</tr>
<tr>
<td>Respiratory Fluoroquinolone (Levofloxacin or Moxifloxacin)</td>
<td>AI</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Alternative</th>
<th>Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>*Beta-lactam plus Doxycycline</td>
<td>BIII</td>
</tr>
</tbody>
</table>

*Preferred beta-lactam = amoxicillin (high-dose) or amoxicillin-CA

*Alternative beta-lactam = cefpodoxime or cefuroxime

Why Not Use Macrolide Monotherapy?
Pneumococcal Antimicrobial Susceptibility Surveillance Data

Tuberculosis in Persons with HIV
Case History: Pulmonary TB

A 42-year-old man is admitted to the hospital with a diagnosis of pulmonary TB. He is started on standard RiPE* therapy. He has no evidence of CNS or pericardial involvement.

2 days later HIV testing results return as positive and further labs show a CD4 count of 26 cells/mm³ and HIV RNA 236,300 copies/mL. An HIV genotype is ordered. He is started on TMP-SMX for PJP prophylaxis.

Testing for HBV and HCV are negative and he has no abnormalities on exam other than pulmonary findings.

*RIPE = rifampin + isoniazid + pyrazinamide + ethambutol

ARS Question 2

One week later he feels much improved and is evaluated to consider starting antiretroviral therapy (ART). What would you recommend now?

1. Defer ART until after 4 weeks of TB therapy
2. Defer ART until after 8 weeks of TB therapy
3. Start ART now and start Prednisone 40 mg daily
4. Start ART now without Prednisone

Adult Opportunistic Infections Guidelines

Initiating Antiretroviral Therapy with Active TB

- CD4 count <50 cells/mm³:
  - Initiate ART as soon as possible, but <2 weeks of starting TB Rx (AI)
- CD4 count ≥50 cells/mm³:
  - Initiate ART <8 weeks of starting TB Rx (AI)

**Adult Opportunistic Infections**

**Guidelines for Preventing TB-IRIS**

- **Indication for Pre-emptive Prednisone therapy**
  - Offer for patients with a CD4 count ≤100 cells/mm³ who are:
    - Starting ART and recently initiated anti-TB therapy,
    - Responding well to TB therapy, and
    - Do not have rifampin resistance, KS, or active HBV

- **Dosing of Pre-emptive Prednisone Therapy**
  - 40 mg/day for 14 days, then 20 mg/day for 14 days


---

**Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS in Persons with HIV**

**Study Design**

- **Background:** Randomized, placebo-controlled double-blind, study to evaluate prednisone pre-emptive therapy in person with HIV diagnosed with TB in South Africa
- **High Risk**
  - Starting ART <30 days of starting TB Rx
  - CD4 <100 cells/mm³
- **Exclusion Criteria**
  - Neurologic TB
  - Rifampin resistance
  - Kaposi's sarcoma
  - HBsAg+
  - Poor response to TB treatment


---

**Pre-emptive Prednisone Reduced TB-Associated IRIS**

- Prednisone: 40 mg/d x 14 days, then 20 mg/d x 14 days (n = 120)
- Placebo (n = 120)


---

**Prednisone Treatment**

- Prednisone treatment was not associated with an increased risk of severe infections or cancers

ARS Question 3: Pulmonary TB

For this man with pulmonary TB on RIPE, which antiretroviral regimen would you recommend?

1. Bictegravir-Tenofovir alafenamide-Emtricitabine
2. Darunavir-cobicistat-tenofovir alafenamide-Emtricitabine
3. Dolutegravir-ritonavir (fixed dose tablet)
4. Dolutegravir 50 mg BID + Tenofovir DF-Emtricitabine

Initial Antiretroviral Options with Rifampin

- NRTIs
  - All OK, use caution with TAF
- NNRTIs
  - Efavirenz: standard dose
- PIs
  - None
- INSTIs
  - Dolutegravir: 50 mg bid
  - Raltegravir: 800 mg bid

Immunizations in Persons with HIV
All persons with HIV should be screened for HBV with:
- HBsAg
- Anti-HBs
- Anti-HBc

• A 28-year-old trans woman (preferred pronouns she/her/hers) recently moved and has a visit to new clinic. She has taken DTG plus TAF-FTC x 6 months.

• Initial clinic labs show CD4 count 824 cells/mm³, HIV RNA <40 copies/mL, HBsAg (-), anti-HBs (-), and anti-HBc (+). She has never received hepatitis B vaccine.
ARS Question 4

- Based on HHS OI Guidelines, what would you recommend now to address the isolated anti-HBc?
  1. Give 1 standard dose HBV vaccine & check anti-HBs in 1-2 months
  2. Give 3-dose series of standard dose HBV vaccine
  3. Check HBV DNA level
  4. She is immune and no further action is needed

Adult Opportunistic Infections Guidelines
Approach to Isolated Anti-HBc in Persons with HIV

Isolated Anti-HBc Positive

Single dose HBV Vaccine

Check anti-HBs in 1-2 Months

Anti-HBs ≥100 mIU/mL
Immune to HBV

Adult Opportunistic Infections Guidelines

Approach to Isolated Anti-HBc in Persons with HIV

- **Isolated Anti-HBc Positive**
  - Single dose HBV Vaccine
  - Check anti-HBs in 1-2 Months
    - Anti-HBs <100 mIU/mL
      - Complete HBV Vaccine Series
      - Check anti-HB in 1-2 Months
    - Anti-HBs ≥100 mIU/mL
      - Immune to HBV


• Persons with HIV and Isolated anti-HBc:
  - Anti-HBs response for >18 months after Hep B Vaccine Booster Dose
    - 100% in those who achieved a titer of 100 IU/mL after booster
    - 23% of those who achieved a titer of 10-100 IU/mL after booster

HBV “Isolated Core Antibody”

Total Hepatitis B Core Antibody (Total Anti-HBc)

Illustration: David H. Spach, MD and David Ehlert, CMI

HBV Infection

 Weeks After Exposure

0 4 8 12 16 20 24 30 36 42 48 52 60 68

Titer

Specific

Total anti-HBs

Infection
Isolated Anti-HBc  
Resolved HBV Infection and Waning Anti-HBs

Isolated Anti-HBs  
Persistent Low-Level HBV Infection with Non-Detectable HBsAg

Unlikely if taking TDF-FTC or TAF-FTC

Pneumococcal Vaccine
Conjugate Pneumococcal Vaccine (PCV13)

Polysaccharide Capsule
Cell Wall
Protein Conjugate

Streptococcus pneumoniae

Polysaccharide Pneumococcal Vaccine (PPSV23)

Polysaccharide Capsule
Cell Wall
Polysaccharide

Streptococcus pneumoniae

Adult Opportunistic Infections Guidelines
Pneumococcal Immunization for Persons with HIV

Pneumococcal Vaccine-Naïve Adults

Age ≥65

PCV13

PPSV23

≥8 wks

Adult Opportunistic Infections Guidelines
Timing of Pneumococcal Vaccine-Naive Adults with HIV

- Timing of PCV13
  - Give regardless of CD4 cell count (AI)
- Timing of 1st Dose PPSV23 if CD4 ≥200 cells/mm³
  - Give ≥8 weeks after PCV13 (AI)
- Timing of 1st Dose PPSV23 if CD4 <200 cells/mm³
  - Defer until CD4 ≥200 cells/mm³ on ART (BIII)
  - Give ≥8 weeks after PCV13 (CIII)


Zoster Vaccine

- Zoster Vaccine Live (ZVL)
- Recombinant Zoster Vaccine (RZV)

Sources: Zoster Vaccine Live (ZVL) and Recombinant Zoster Vaccine (RZV)
Adult Opportunistic Infections Guidelines
Zoster Vaccine in Persons with HIV

<table>
<thead>
<tr>
<th>Zoster Vaccine in Persons with HIV</th>
<th>Age</th>
<th>CD4</th>
<th>Dosing</th>
<th>Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preferred</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recombinant Zoster Vaccine (RZV)</td>
<td>≥50 yrs</td>
<td>Any</td>
<td>2-Doses 2, 6 months</td>
<td>AIII</td>
</tr>
<tr>
<td>Alternative</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Zoster Vaccine Live (ZVL)</td>
<td>≥50 yrs</td>
<td>≥200</td>
<td>1-Dose</td>
<td>BIII</td>
</tr>
<tr>
<td>*ZVL contraindicated in persons with a CD4 count &lt;200 cells/mm³ (AIII)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Top 5 Key Points

- HIV CAP Rx: (1) macrolide + beta lactam or (2) respiratory FQ
- Starting ART in person with TB: offer prednisone if CD4 <100
- Isolated HBcAb: start with a booster dose of Hep B vaccine
- PCV13 Vaccine: do not delay if CD4 <200
- Zoster Vaccine: Give RZV to all ≥50 years of age